RedHill Biopharma (RDHL) Accumulated Expenses (2016 - 2025)

RedHill Biopharma (RDHL) has reported Accumulated Expenses for 10 consecutive years, with $12.0 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Accumulated Expenses rose 20.24% year-over-year to $12.0 million in Q4 2025; TTM through Dec 2025 was $12.0 million, a 20.24% increase from a year earlier, with the FY2025 full-year figure at $12.0 million, up 20.24% from the prior year.
• Accumulated Expenses was $12.0 million for Q4 2025 at RedHill Biopharma, up from $10.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $25.4 million in Q1 2021 and troughed at $4.0 million in Q2 2024.
• A 5-year average of $16.0 million and a median of $17.9 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses tumbled 74.42% in 2023 and soared 169.78% in 2025, its largest moves.
• Over 5 years, Accumulated Expenses stood at $20.9 million in 2021, then slipped by 14.1% to $17.9 million in 2022, then plunged by 74.42% to $4.6 million in 2023, then surged by 117.62% to $10.0 million in 2024, then increased by 20.24% to $12.0 million in 2025.
• The last three Accumulated Expenses figures came in at $12.0 million (Q4 2025), $10.7 million (Q2 2025), and $10.0 million (Q4 2024), per Business Quant data.